New drug improves survival in multiple myeloma patients: Lancet

A therapeutic drug, called lenalidomide, has shown improved outcomes and survival rates in patients with a serious type of bone marrow cancer (multiple myeloma), according to a largest of its kind of study.

The study published in The Lancet Oncology, show an improvement for those who received ongoing therapy with the drug lenalidomide, compared to those not receiving it. This offers a new hope with this disease.

Read more at: